



# Biotech Daily

Thursday November 26, 2020

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH EVEN: IMPEDIMED UP 10%; RESONANCE DOWN 6%**
- \* **AROA H1 REVENUE DOWN 30% TO \$8.7m, LOSS UP 1440% TO \$13m**
- \* **OSPREY, BIOCORE US DYEVERT DEAL ADDS 8 N-E STATES**
- \* **RACE: GEORGE CLINICAL FOR BISANTRENE BREAST CANCER TRIAL**
- \* **DIIS APPROVES RECCE OVERSEAS R&D; EXPECTS \$7.5m**
- \* **MEDADVISOR \$2.6m UNNAMED US BIOPHARMA DEAL**
- \* **ANTEOTECH FINALIZES SARS-COV-2 TEST**
- \* **SUDA AGM 63% DEFEAT OPTIONS, 57% REM REPORT 1<sup>st</sup> STRIKE**
- \* **LBT AGM 41% REM REPORT 1<sup>st</sup> STRIKE, PLACEMENT CAPACITY LOST**
- \* **ANATARA AGM 24% OPPOSE 10% PLACEMENT CAPACITY**
- \* **OPTISCAN WITHDRAWS 2 AGM RESOLUTIONS**
- \* **BARD1 30-TO-1 CONSOLIDATION TIMETABLE**
- \* **BIO-MELBOURNE 'PREPARING FOR INDUSTRY ENGAGEMENT' FORUM**

## MARKET REPORT

The Australian stock market fell 0.7 percent on Thursday November 26, 2020, with the ASX200 down 46.9 points to 6,636.4 points. Sixteen of the Biotech Daily Top 40 stocks were up, 16 fell and eight traded unchanged.

Impedimed was the best for the second day in a row, up 1.5 cents or 10.3 percent to 16 cents, with 8.7 million shares traded. Next Science and Universal Biosensors climbed more than five percent; Actinogen, Amplia, Cyclopharm and Telix improved more than four percent; Medical Developments, Paradigm and Uscom were up more than three percent; Avita, Nova Eye and Prescient rose more than two percent; Nanosonics was up 1.1 percent; with Polynovo, Pro Medicus and Resmed up by less than one percent.

Resonance led the falls, down one cent or 5.7 percent to 16.5 cents, with 480,814 shares traded. Compumedics lost 5.45 percent; Cynata, Imugene, Orthocell and Volpara fell more than four percent; Oncosil was down three percent; Alterity, Dimerix, Genetic Signatures, Neuren and Opthea shed two percent or more; with Cochlear, CSL, Kazia, Mesoblast, Proteomics and Starpharma down one percent or more.

## AROA BIOSURGERY

Aroa says revenue for the six months to September 30, 2020 was down 30.3 percent to \$NZ9,180,000 (\$A8,729,150), with net loss after tax up 1,440.3 percent to \$NZ13,493,000 (\$A12,826,990).

Aroa said revenue came primarily from sales of products, including its Myriad for soft tissue repair and Symphony for wound closure, which were impacted by restrictions on elective surgery caused by the Covid-19 pandemic, with remaining revenue from royalties and project fees.

The company said it had cash and cash equivalents of \$NZ18,683,000 at September 30, 2020 compared to \$NZ3,850,000 at March 31, 2020.

Aroa fell 5.5 cents or 4.2 percent to \$1.26 with 817,701 shares traded.

## OSPREY MEDICAL

Osprey says it has a two-year agreement with Biocore Inc to market its Dyevert cardiac dye minimization devices in eight states in the north-eastern US.

Osprey said the Elkridge, Maryland-based Biocore specialized in the sale of cardiac technology products and its sales representatives would sell Dyevert in north-eastern US states outside Osprey's current sales reach.

The company said the agreement was an independent sales agency model which would allow Osprey to sell Dyevert through both distributors and direct sales.

Osprey said it would supply Dyevert to hospitals in the independent sales agency area and pay commissions to the agency based on total revenues.

The company said the agreement had escalating quarterly sales targets and aimed to expand Osprey's geographic coverage in the near-term.

Osprey chief executive officer Mike McCormick said the company's partnership with Biocore would "help strengthen our market presence in the north-eastern states in which we currently do not have a presence".

"It can be a costly process to enter new areas, especially during Covid-19 and the introduction of the [independent sales agency] model will enable us to expand across the US in the most cost-effective and sustainable way", Mr McCormick said.

Osprey was unchanged at 2.2 cents with 5.1 million shares traded.

## RACE ONCOLOGY

Race says it has appointed George Clinical to scope and cost a proof-of-concept, phase I/II, trial of Bisantrene with cyclophosphamide for breast cancer.

Earlier this week, Race said that an in-vitro study conducted by New South Wales' University of Newcastle found that Bisantrene combined with the chemotherapy drug cyclophosphamide had similar efficacy to the standard-of-care for breast cancer, results providing the necessary pre-clinical data to advance Bisantrene to in-human breast cancer clinical trials. (BD: May 14, Nov 24, 2020).

Today, the company said that Sydney's George Clinical would organize the trial within about 13 weeks, including the appointment of principle investigators trial sites, as well as determining costs and possible regulatory hurdles.

Race was up 13 cents or seven percent to \$1.98 with 1.4 million shares traded.

## RECCE PHARMACEUTICALS

Recce says the Federal Department of Industry Innovation and Science has approved its off-shore claims for the Research and Development Tax incentive.

Recce said the advanced overseas finding related to expenditure of \$17,150,000 for its synthetic antibiotics program for the three years to June 30, 2022.

The company said it expected to receive a tax incentive of 43.5 percent and Biotech Daily calculates that Recce will receive \$7,460,250.

Recce was unchanged at \$1.13.

## MEDADVISOR

Medadvisor says its subsidiary, Adheris Health, has a \$US1.89 million (\$A2.6 million) agreement with an unnamed company for its medication adherence program.

Earlier this month, Medadvisor said it had raised \$35 million in a placement and rights offer 38 cents a share to acquire the Burlington, Massachusetts-based Adheris Health and its direct-to-patient medication adherence program (BD: Nov 12, 2020).

Today, the company said it could not disclose the name of the US company but it was listed on an US exchange and had a market capitalization of more than \$US70 billion.

Medadvisor said the agreement was a one-year renewal of a previous program.

Medadvisor fell 2.5 cents or 6.1 percent to 38.5 cents with 1.4 million shares traded.

## ANTEOTECH

Anteotech says it has declared a design freeze for its Sars-Cov-2 rapid antigen test, after saliva sampling found that the test can detect the virus in artificial mucus.

Anteotech said a design freeze was “the point at which the technical work and inputs are locked in” and marked that the test was on schedule and within budget.

Last month, the company said an in-vitro study found that the severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) antigen test is “highly sensitive” (BD: Oct 21, 2020).

Today, Anteotech said the test could provide results in less than 15 minutes with high sensitivity using naso-pharyngeal swabs and it was “on track” to begin trials this year.

Anteotech was up 2.1 cents or 26.6 percent to 10 cents with 22.9 million shares traded.

## SUDA PHARMACEUTICALS

Suda says its annual general meeting voted 57 percent against the remuneration report with up to 63 percent opposing 3,000,000 options for director Dr Michael Baker.

Suda said 19,071,580 votes (56.95%) opposed the remuneration report.

Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 any company sustaining a vote of 25 percent or more against the remuneration report in two successive annual meetings is required to vote on a board spill and if passed the directors must stand for re-election.

The company said the resolutions to issue 3,000,000 options to Dr Baker, exercisable in three tranches at 5.5 cents, 6.5 cents and 7.5 cents each, respectively, within three years was opposed by 20,147,740 votes (62.83%) with the employee share option plan defeated by a smaller majority, with other resolutions passed more easily.

According to the company’s most recent Appendix 2A new issue announcement, Suda had 306,835,902 on issue, meaning the votes against Dr Baker’s options amounted to 6.6 percent of the company, sufficient to call extraordinary general meetings.

Suda was up 0.3 cents or 7.1 percent to 4.5 cents with 1.7 million shares traded.

## LBT INNOVATIONS

LBT says its annual general meeting faced up to 44.23 percent opposition, including a remuneration report first strike and the loss of the 10 percent placement capacity.

LBT said the greatest dissent was against the issue of 6,000,000 long term incentive options to managing-director Brent Barnes, which had 54,145,365 votes (44.23%) against. The company said that resolutions to issue shares in lieu of cash salary and bonuses to Mr Barnes were opposed by 39.22 percent and 39.92 percent respectively.

LBT said the remuneration report earned a first strike with 48,391,303 votes (40.57%) against and 70,895,075 votes (58.43%) in favor.

Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 any company sustaining a vote of 25 percent or more against the remuneration report in two successive annual meetings is required to vote on a board spill and if passed the directors must stand for re-election.

The company said the proposed 10 percent placement capacity, which required a 75 percent majority, was lost with 37.63 percent against, while the remaining resolutions passed, with up-to 42.81 percent of votes against.

The company's most recent Appendix 2A new issue announcement said that LBT had 288,742,895 shares on issue, meaning that the votes against Mr Barnes incentive options amounted to 18.75 percent of the company, sufficient to call extraordinary meetings.

LBT was unchanged at 12.5 cents.

## ANATARA LIFESCIENCES

Anatara says its annual general meeting has carried all resolutions, but with 24.07 opposition to the 10 percent placement capacity, which needs a 75 percent majority.

Anatara said 5,031,739 votes (24.07%) opposed the placement capacity, while resolutions to issue options in lieu of fees to chair Sue MacLeman and directors Dr Jane Ryan and Dr David Brookes were opposed by up-to 10.18 percent of the meeting.

Anatara said the remuneration report and the remaining resolutions passing more easily.

According to the company's most recent Appendix 2A new issue announcement, Anatara had 66,783,270 shares on issue, meaning the votes against the 10 percent placement capacity amounted to 7.5 percent of the company, sufficient to call extraordinary general meetings.

Anatara was up two cents or 11.4 percent to 19.5 cents.

## OPTISCAN IMAGING

Optiscan says it has withdrawn two resolutions ahead of today's annual general meeting. Optiscan did not disclose the nature of the resolutions, citing their numbers as "six" and "seven".

Last month in its notice of meeting, the company said resolution six proposed to issue up to 6,000,000 options exercisable at 15 cents each to executive chair Darren Lurie and resolution seven was the 10 percent placement facility (BD: Oct 27, 2020).

Today, Optiscan said the withdrawal of the resolutions would not affect the validity of the proxy form or any proxy votes already made.

The company meeting results said that all resolutions passed easily with up to 3.23 percent dissent against the issue of 22,371,250 options to Orchid Capital 8,771,058 votes against the renewal of proportional takeover provisions.

Optiscan was unchanged at 10 cents.

## [BARD1 LIFE SCIENCES](#)

Bard1 says its proposed 30-to-one consolidation is expected to be completed on Monday, December 7, 2020.

In an announcement to the ASX ahead of today's annual general meeting which will vote on the consolidation, Bard1 said the record date for shares and options to be consolidated would be December 2, 2020.

The company said the consolidation would reduce its number of shares on offer from 2,394,530,384 shares to 79,817,679 shares and increase its share price from today's closing price of 2.4 cents to 72 cents.

Bard1 said the number of options on offer would reduce from 47,795,332 options to 1,593,178 options, with performance shares to reduce from 217,003,236 performance shares to 7,233,441 performance shares, with commensurate 30-fold increases in exercise prices.

Bard1 was unchanged at 2.3 cents with 9.4 million shares traded.

## [BIO-MELBOURNE NETWORK](#)

The Bio-Melbourne Network says it is hosting a Bio-Forum, titled 'Getting Your Ducks in a Row: Preparing for Meaningful Engagement with Industry'.

The Network said the event would provide participants with "a deeper understanding of the product development eco-system and why engagement with industry is integral to successful translation of a novel research endeavour into a viable product.

The Network said the panel included it was pleased to welcome industry experts the Royal Melbourne Institute's head of research partnerships and initiatives Clare Russell, Tricycle Developments head of innovation and strategy Luke Martin, Hydrix corporate development head Peter Lewis, AusIndustry's Entrepreneurs' Program commercialization facilitator Andre Tan and Navi Medical Technologies co-founder and chief financial officer Wei Sue.

The Bio-Melbourne Network said that the Victoria Government supported the event.

The Network said the virtual event would be held on December 1, 2020 from 9-10:30am (AEDT) and to register, go to: <https://bit.ly/3nFm7eg>.

For details, go to: <https://biomelbourne.org/event/bioforum-getting-your-ducks-in-a-row/>.